The start of something?

The start of something?

This morning privately held Intarcia Therapeutics announced the FDA has accepted the NDA for the Medici system, a micropump which delivers exenatide. As we have seen from recent earning reports the GLP-1 category continues to gain strength and is one of the few bright spots when it comes to diabetes therapy options. As we predicted the category has grown with each improvement in delivery options. Byetta begin this process with twice-daily injections, Victoza helped things along being a once-daily injection and now Trulicity, Bydureon and Tanzeum are moving it further into the mainstream with once-weekly injections . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.